Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism

International Journal of Cancer

Volumn 139, Issue 8, 2016, Pages 1776-1787

  Phillips, Emma ^a   Lang, Verena ^a   Bohlen, Jonathan ^a   Bethke, Frederic ^a   Puccio, Laura ^a   Tichy, Diana ^a   Herold Mende, Christel ^b   Hielscher, Thomas ^a   Lichter, Peter ^a   Goidts, Violaine ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

atypical protein kinase C iota; glioblastoma; glioblastoma stem like cells; notch signaling

Indexed keywords

AUROTHIOMALATE; NOTCH1 RECEPTOR; PROTEIN INHIBITOR; PROTEIN KINASE C IOTA; PSEUDOSUBSTRATE PEPTIDE INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION PROFILING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; STEM CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84981187962     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30234     Document Type: Article

References (37)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
2. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821–8.
3. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396–401.
4. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391–403.
5. Ernst A, Hofmann S, Ahmadi R, et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res 2009;15:6541–50.
6. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756–60.
7. Eramo A, Ricci-Vitiani L, Zeuner A, et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006;13:1238–41.
8. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67
9. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157–73.
10. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012;22:425–37.
11. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98–110.
12. Goidts V, Bageritz J, Puccio L, et al. RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene 2012;31:3235–43.
13. Takagawa R, Akimoto K, Ichikawa Y, et al. High expression of atypical protein kinase C lambda/iota in gastric cancer as a prognostic factor for recurrence. Ann Surg Oncol 2010;17:81–8.
14. Murray NR, Jamieson L, Yu W, et al. Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol 2004;164:797–802.
15. Yang YL, Chu JY, Luo ML, et al. Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer 2008;47:127–36.
16. Du GS, Wang JM, Lu JX, et al. Expression of P-aPKC-iota, E-cadherin, and beta-catenin related to invasion and metastasis in hepatocellular carcinoma. Ann Surg Oncol 2009;16:1578–86.
17. Kojima Y, Akimoto K, Nagashima Y, et al. The overexpression and altered localization of the atypical protein kinase C lambda/iota in breast cancer correlates with the pathologic type of these tumors. Hum Pathol 2008;39:824–31.
18. Ishiguro H, Akimoto K, Nagashima Y, et al. aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci U S A 2009;106:16369–74.
19. Regala RP, Weems C, Jamieson L, et al. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 2005;65:8905–11.
20. Scotti ML, Bamlet WR, Smyrk TC, et al. Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Res 2010;70:2064–74.
21. Kusne Y, Carrera-Silva EA, Perry AS, et al. Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFalpha in glioblastoma. Sci Signal 2014;7:ra75
22. Campos B, Wan F, Farhadi M, et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 2010;16:2715–28.
23. Iovino M, Patani R, Watts C, et al. Human stem cell-derived neurons: a system to study human tau function and dysfunction. PLoS One 2010;5:e13947
24. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B 1995;57:289–300.
25. Gravendeel LA, Kouwenhoven MC, Gevaert O, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009;69:9065–72.
26. Baldwin RM, Parolin DA, Lorimer IA. Regulation of glioblastoma cell invasion by PKC iota and RhoB. Oncogene 2008;27:3587–95.
27. Kanzaki M, Mora S, Hwang JB, et al. Atypical protein kinase C (PKCzeta/lambda) is a convergent downstream target of the insulin-stimulated phosphatidylinositol 3-kinase and TC10 signaling pathways. J Cell Biol 2004;164:279–90.
28. Stallings-Mann M, Jamieson L, Regala RP, et al. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res 2006;66:1767–74.
29. Regala RP, Thompson EA, Fields AP. Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells. Cancer Res 2008;68:5888–95.
30. Campos B, Gal Z, Baader A, et al. Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma. J Pathol 2014;234:23–33.
31. Murray NR, Kalari KR, Fields AP. Protein kinase Ciota expression and oncogenic signaling mechanisms in cancer. J Cell Physiol 2011;226:879–87.
32. Mansfield A, Fields A, Jatoi A, et al. 2013 ASCO Annual Meeting, Chicago, Illinios.
33. Kanamori M, Kawaguchi T, Nigro JM, et al. Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg 2007;106:417–27.
34. Fan X, Khaki L, Zhu TS, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010;28:5–16.
35. Sjoqvist M, Antfolk D, Ferraris S, et al. PKCzeta regulates Notch receptor routing and activity in a Notch signaling-dependent manner. Cell Res 2014;24:433–50.
36. Mah IK, Soloff R, Hedrick SM, et al. Atypical PKC-iota Controls Stem Cell Expansion via Regulation of the Notch Pathway. Stem Cell Reports 2015;5:866–80.
37. Butler AM, Scotti Buzhardt ML, Erdogan E, et al. A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion. Oncotarget, 2015;6:15297–310